| Item Type | Name |
|
Academic Article
|
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.
|
|
Academic Article
|
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
|
|
Academic Article
|
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
|
|
Academic Article
|
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
|
|
Academic Article
|
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
|
|
Academic Article
|
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
|
|
Academic Article
|
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
|
|
Academic Article
|
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.
|
|
Academic Article
|
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
|
|
Academic Article
|
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
|
|
Academic Article
|
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
|
|
Academic Article
|
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
|
|
Academic Article
|
Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
|
|
Academic Article
|
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.
|
|
Academic Article
|
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
|
|
Academic Article
|
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
|
|
Academic Article
|
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
|
|
Academic Article
|
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
|
|
Academic Article
|
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
|
|
Academic Article
|
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
|
|
Academic Article
|
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
|
|
Academic Article
|
Estrogen-receptor biology: continuing progress and therapeutic implications.
|
|
Academic Article
|
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
|
|
Academic Article
|
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
|
|
Academic Article
|
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
|
|
Academic Article
|
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
|
|
Academic Article
|
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
|
|
Academic Article
|
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
|
|
Academic Article
|
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
|
|
Academic Article
|
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
|
|
Academic Article
|
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
|
|
Academic Article
|
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
|
|
Academic Article
|
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
|
|
Academic Article
|
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
|
|
Academic Article
|
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
|
|
Academic Article
|
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
|
|
Academic Article
|
Mechanisms of tamoxifen resistance.
|
|
Academic Article
|
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
|
|
Academic Article
|
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
|
|
Academic Article
|
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.
|
|
Concept
|
Tamoxifen
|
|
Academic Article
|
Cancer Res
|
|
Academic Article
|
Correlations between Genetic Variants in CYP2D6 and UGT2B7 and Survival in Breast Cancer Patients Treated with or without Tamoxifen: Results from a Large Cohort Study
|
|
Academic Article
|
SABCS
|
|
Academic Article
|
Combined chemo-hormonal therapy in breast cancer: a hypothesis.
|
|
Academic Article
|
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase.
|
|
Academic Article
|
Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
|
|
Academic Article
|
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
|
|
Academic Article
|
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
|
|
Academic Article
|
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
|
|
Academic Article
|
Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.
|
|
Academic Article
|
Biological differences among MCF-7 human breast cancer cell lines from different laboratories.
|
|
Academic Article
|
Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy.
|
|
Academic Article
|
Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration.
|
|
Academic Article
|
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.
|
|
Academic Article
|
Adjuvant treatment of node-negative breast cancer.
|
|
Academic Article
|
Adjuvant therapy in node-negative breast cancer. A panel discussion.
|
|
Academic Article
|
Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells.
|
|
Academic Article
|
Tumor and serum tamoxifen concentrations in the athymic nude mouse.
|
|
Academic Article
|
Tamoxifen in premenopausal patients with metastatic breast cancer: a review.
|
|
Academic Article
|
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.
|
|
Academic Article
|
Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients.
|
|
Academic Article
|
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.
|
|
Academic Article
|
Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors.
|
|
Academic Article
|
Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism.
|
|
Academic Article
|
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
|
|
Academic Article
|
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
|
|
Academic Article
|
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
|
|
Academic Article
|
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
|
|
Academic Article
|
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
|
|
Academic Article
|
Oestrogen receptors and breast cancer.
|
|
Academic Article
|
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
|
|
Academic Article
|
Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
|
|
Academic Article
|
Tamoxifen in the treatment of breast cancer.
|
|
Academic Article
|
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
|
|
Academic Article
|
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
|
|
Academic Article
|
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
|
|
Academic Article
|
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
|